Question explored with the scientific record
treatment for ocular melanoma eye tumour
The short version: eye-sparing radiation controls the eye tumor in most cases, but it does not clearly extend life, and the adjuvant chemo data is weak.
For most uveal melanomas the first decision is how to save the eye without pretending that saves the patient. Plaque brachytherapy (a radioactive seed sewn onto the eye) held local control around 91% at five years in 190 patients, with 9% local failure and 12% distant spread [2]. Proton beam did even better locally: 96% five-year local control in 1,406 patients, with 79% overall survival [6]. But a US registry of 2,054 patients found five-year survival stuck near 80% for 25 years, even as surgery gave way to radiation [4]. That flat line is the honest headline: local control is real, survival benefit from the choice of local therapy is not established.
The trade is vision and eye complications. Proton beam left about 60% with worse vision and 31.5% with complications [3]. Plaque radiation caused cataract in 55%, retinopathy in 24%, and glaucoma in 15% of ciliary-body cases [5]. Higher radiation dose bought more vision loss without better tumor control [2].
| Outcome | Plaque (125-I) | Proton beam |
|---|---|---|
| 5-year local control | 91% [2] | 96% [6] |
| 5-year overall survival | 84% [2] | 79% [6] |
| Vision loss / complications | dose-dependent [2] | ~60% vision drop [3] |
The adjuvant chemotherapy trial was nonrandomized, compared treated patients to a separate observation group, and enrolled only 62 of 150 screened [1]. That is a weak design, and it should not be sold as proof.
My call: for a tumor that can be radiated, eye-sparing radiation is reasonable for local control, but no retrieved trial shows it extends life, and the adjuvant drug evidence is thin. Confidence: moderate on local control, low on any survival benefit from treatment choice.
Sources used 6
-
A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes
A nonrandomized prospective phase II trial evaluating sequential low-dose dacarbazine and interferon-α2b as adjuvant therapy for high-risk uveal melanoma (monosomy 3) to assess 5-year metastasis-free and overall survival compared with observation.
DOI: 10.1136/bjophthalmol-2019-314461 -
Uveal Melanoma Treated With Iodine-125 Episcleral Plaque: An Analysis of Dose on Disease Control and Visual Outcomes
This retrospective study of 190 patients with uveal melanoma treated with iodine-125 plaque brachytherapy found that while increasing radiation doses correlated with greater visual acuity loss and radiation complications, they did not affect tumor control outcomes.
DOI: 10.1016/j.ijrobp.2014.01.026 -
Transplantable Melanomas in Hamsters and Gerbils as Models for Human Melanoma. Sensitization in Melanoma Radiotherapy—From Animal Models to Clinical Trials
Pigmented Bomirski hamster melanomas and Zeman UJ90 gerbil melanomas reveal pigmentation-dependent radiotherapy responses, with melanogenesis often conferring radioresistance in some models and its inhibition enhancing radiosensitivity, informing potential translational strategi…
DOI: 10.3390/ijms19041048 -
Survival rates with uveal melanoma in the United States: 1973–1997
A population-based SEER analysis (1973–1997) found that 5-year relative survival for primary uveal melanoma in the United States remained about 80% over 25 years, with no improvement in survival despite increasing use of globe-conserving therapies and shifts between surgery and …
DOI: 10.1016/s0161-6420(03)00077-0 -
Management of ciliary body melanoma with iodine-125 plaque brachytherapy
A retrospective, nonrandomized case series evaluating presentation, management, and outcomes of 42 patients with ciliary body melanoma treated with iodine-125 plaque brachytherapy, showing high tumor control and eye preservation but notable radiation-related ocular morbidity.
DOI: 10.3129/i09-097 -
Proton beam radiotherapy for uveal melanoma: Results of Curie Institut–Orsay Proton Therapy Center (ICPO)
This study reports on the outcomes of proton beam radiotherapy for uveal melanoma in 1,406 patients treated at the Curie Institut-Orsay Proton Therapy Center, highlighting a 5-year overall survival rate of 79% and a local control rate of 96%.
DOI: 10.1016/j.ijrobp.2006.01.020